VENTRA PD-L1 (SP142) assays provide evidence of TNBC patients eligible for atezolizumab treatment and suggest that atezolizumab treatment would be of benefit in TNBC with PD-L1 expression in 1% or more of tumor-infiltrating immune cells (15, 16). Here, CD274 is linked to neoplasm.